RE:RE:RE:RE:RE:RE:RE:Accelerated Approval ahead of AUA congress would spark
Eoganacht wrote: Hi Rumple - Roswell Park is already treating 3 types of skin cancer with pdt off-label - basal cell carcinoma, (the most common form of skin cancer), Bowen's disease, and Nevoid basal cell carcinoma syndrome. Since these cancers are already being treated with off-label photosenstizers, once TLD1433 is approved for NMIBC, maybe they could use TLD1433 instead.
Rumpl3StiltSkin Wrote:
Thanks Eoga,
Very interesting. Skin Cancers, in total, look like a promising area for TLT. And a Giant market.
If/when TLD-1433 is proven successful, there's a very good chance that Roswell would incorporate TLD-1433 into "all" of their PDT cancer treatment protocols. My opinion is based on their strong historical interest in/study of our photosensitizer (with the hopes of replacing Photofrin) for their NSCLC/Mesothelioma indications.
The Roswell PDT dept. is always in search for a new & better photosensitizer/dosimetry, & once our ACT is proven in NMIBC, I believe they would be one of the first institutions to replace Photofrin with our compound. Since many centers have followed Roswell's lead in the PDT arena, further success at Roswell could translate into a pretty rapid/widespread adoption of out tech...all imo.